Heart failure is a major public health problem because of its high prevalence and impact on mortality, morbidity, quality of life, and social costs. The aim of this analysis was to estimate the effects of the novel inodilator levosimendan versus standard inotropic therapy (ST) of dobutamine in acute heart failure. A study population of 292 patients with acute heart failure was derived from an observational registry of patients referred to our department. Of these, 147 patients received iv levosimendan (0.05-0.1 mu g.kg(-1).min(-1) for 24 hours), and 145 patients were treated with ST. Duration of hospitalization, survival at 1 month, and the rehospitalization rate during the year after the index hospitalization were evaluated. Cost-effectiveness analysis was performed. The mean length of hospitalization was 12.08 and 13.57 days in the levosimendan and ST groups, respectively (P, 0.05). Rehospitalization rates were lower in the levosimendan group at 6 months (1.44% vs. 2.3%; P < 0.05) and 12 months (7.6% vs. 14.3%; P < 0.05). Mortality rate at 1 month was 2.1% versus 6.9% in the levosimendan and ST groups, respectively (P < 0.05). The percapita cost of treatment with levosimendan was (sic)78.86 higher than that with ST during the first hospitalization but (sis)280.22 lower when the rehospitalization rate was considered.

Cost-effectiveness of Levosimendan in Patients With Acute Heart Failure / Fedele, Francesco; D'Ambrosi, Alessandra; Bruno, Noemi; Caira, Carmen; Brasolin, Bruno; Mancone, Massimo. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. - ISSN 0160-2446. - ELETTRONICO. - 58:4(2011), pp. 363-366. [10.1097/fjc.0b013e318224e0a2]

Cost-effectiveness of Levosimendan in Patients With Acute Heart Failure

FEDELE, Francesco;D'AMBROSI, ALESSANDRA;BRUNO, Noemi;CAIRA, CARMEN;BRASOLIN, BRUNO;MANCONE, Massimo
2011

Abstract

Heart failure is a major public health problem because of its high prevalence and impact on mortality, morbidity, quality of life, and social costs. The aim of this analysis was to estimate the effects of the novel inodilator levosimendan versus standard inotropic therapy (ST) of dobutamine in acute heart failure. A study population of 292 patients with acute heart failure was derived from an observational registry of patients referred to our department. Of these, 147 patients received iv levosimendan (0.05-0.1 mu g.kg(-1).min(-1) for 24 hours), and 145 patients were treated with ST. Duration of hospitalization, survival at 1 month, and the rehospitalization rate during the year after the index hospitalization were evaluated. Cost-effectiveness analysis was performed. The mean length of hospitalization was 12.08 and 13.57 days in the levosimendan and ST groups, respectively (P, 0.05). Rehospitalization rates were lower in the levosimendan group at 6 months (1.44% vs. 2.3%; P < 0.05) and 12 months (7.6% vs. 14.3%; P < 0.05). Mortality rate at 1 month was 2.1% versus 6.9% in the levosimendan and ST groups, respectively (P < 0.05). The percapita cost of treatment with levosimendan was (sic)78.86 higher than that with ST during the first hospitalization but (sis)280.22 lower when the rehospitalization rate was considered.
2011
acute heart failure; hospitalization costs; inodilator therapy; rehospitalization rate; survival
01 Pubblicazione su rivista::01a Articolo in rivista
Cost-effectiveness of Levosimendan in Patients With Acute Heart Failure / Fedele, Francesco; D'Ambrosi, Alessandra; Bruno, Noemi; Caira, Carmen; Brasolin, Bruno; Mancone, Massimo. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. - ISSN 0160-2446. - ELETTRONICO. - 58:4(2011), pp. 363-366. [10.1097/fjc.0b013e318224e0a2]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/434572
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact